Mesenchymal stem cell delivery routes and fate
Related Experiment Video
Updated: Apr 29, 2026
Isolation of Human BAMBIhighMFGE8high Umbilical Cord-Derived Mesenchymal Stromal Cells
Published on: January 10, 2025
1Charité Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.
Abstract:
MSC have been used in diverse animal disease models to investigate their regenerative capacity. Although the clinical outcome was often encouraging, the mode of action of the cells remains unresolved. Differentiation of MSC into cell types of their target organs was only rarely shown, with the exception of the musculoskeletal system. Thus, the effect of the cells on the clinical outcome in several disease models of tissue degeneration must be independent of trans-differentiation and caused by indirect or paracrine effects. Furthermore, tracking of the cells in vivo revealed that only a small proportion of the cells home and persists in the target sites, and that most of the cells are not detectable after 7∼14 days post transplantation. It seems that MSC can deliver a profound clinical effect without trans-differentiation, without homing to target organs in significant numbers and despite the cell's disappearance within short periods of time. These finding also suggest that the full potency of MSC has not yet been exploited in the current applications. Here we will provide an overview of the different routes used for cell delivery and the fate of the cells after transplantation. The effects on clinical outcome are discussed with respect to the role cell entrapment in non-target organs may play for the observed clinical effects.
Insights
Mesenchymal stem cells (MSCs) provide significant clinical benefits in animal disease models, likely through paracrine effects rather than direct differentiation or long-term engraftment. Their potency may be further enhanced by optimizing delivery and considering non-target organ interactions.
Area of Science:
- Regenerative Medicine
- Cell Therapy
- Animal Models of Disease
Background:
- Mesenchymal stem cells (MSCs) show promise in treating various animal diseases, but their mechanism of action is unclear.
- Clinical outcomes are often positive, yet MSC differentiation into target organ cells is rare, except in the musculoskeletal system.
Purpose of the Study:
- To investigate the unresolved mode of action of MSCs in animal disease models.
- To explore the role of indirect or paracrine effects in MSC-mediated clinical outcomes.
- To review cell delivery routes, in vivo fate, and potential contributions of non-target organ entrapment.
Main Methods:
- Review of existing literature on MSC transplantation in animal disease models.
- Analysis of studies tracking MSCs in vivo post-transplantation.
- Discussion of cell delivery routes and the fate of transplanted MSCs.
Main Results:
- MSC effects appear independent of trans-differentiation and significant long-term homing to target sites.
- Most transplanted MSCs are undetectable within 7-14 days, suggesting transient presence.
- Clinical benefits are observed despite limited cell persistence and differentiation.
Conclusions:
- The therapeutic efficacy of MSCs likely stems from indirect or paracrine signaling, not solely from cell replacement.
- Current MSC applications may not fully leverage their therapeutic potential.
- Further research into cell delivery strategies and the impact of non-target organ entrapment is warranted.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...